|Datasheet||Specific References||Reviews||Related Products||Protocols|
|Vector Type||Mammalian Expression Vector|
|Expression Method||Constiutive, Stable / Transient|
|Selection In Mammalian Cells||Hygromycin|
Human influenza hemagglutinin (HA) is a surface glycoprotein required for the infectivity of the human virus. The HA tag is derived from the HA-molecule corresponding to amino acids 98-106 has been extensively used as a general epitope tag in expression vectors. Many recombinant proteins have been engineered to express the HA tag, which does not appear to interfere with the bioactivity or the biodistribution of the recombinant protein. This tag facilitates the detection, isolation, and purification of the proteins.
The actual HA tag is as follows: 5' TAC CCA TAC GAT GTT CCA GAT TAC GCT 3' or 5' TAT CCA TAT GAT GTT CCA GAT TAT GCT 3' The amino acid sequence is: YPYDVPDYA.
|Mouse IGF-II ORF mammalian expression plasmid, C-GFPSpark tag||MG50040-ACG|
|Mouse IGF-II ORF mammalian expression plasmid, C-OFPSpark / RFP tag||MG50040-ACR|
|Mouse IGF-II ORF mammalian expression plasmid, C-Flag tag||MG50040-CF|
|Mouse IGF-II ORF mammalian expression plasmid, C-His tag||MG50040-CH|
|Mouse IGF-II ORF mammalian expression plasmid, C-Myc tag||MG50040-CM|
|Mouse IGF-II ORF mammalian expression plasmid, C-HA tag||MG50040-CY|
|Mouse IGF-II Gene cDNA clone plasmid||MG50040-M|
|Mouse IGF-II ORF mammalian expression plasmid, N-Flag tag||MG50040-NF|
|Mouse IGF-II ORF mammalian expression plasmid, N-His tag||MG50040-NH|
|Mouse IGF-II ORF mammalian expression plasmid, N-Myc tag||MG50040-NM|
|Mouse IGF-II ORF mammalian expression plasmid, N-HA tag||MG50040-NY|
|Mouse IGF-II natural ORF mammalian expression plasmid||MG50040-UT|
|Learn more about expression Vectors|
Insulin-like growth factor 2 (IGF-2/IGF-II) is a member of the insulin family of polypeptide growth factors, which are involved in development and growth. It is an imprinted gene, expressed only from the paternal allele, and epigenetic changes at this locus are associated with Wilms tumour, Beckwith-Wiedemann syndrome, rhabdomyosarcoma, and Silver-Russell syndrome. IGF-2/IGF-II is a mediator of prolactin-induced alveologenesis; prolactin, IGF-2, and cyclin D1, all of which are overexpressed in breast cancers, are components of a developmental pathway in the mammary gland. IGF-2 and exhibited statistically significant, positive associations with colorectal cancer risk when cases were confined to those diagnosed within a relatively short time period after enrolment. Circulating IGF-2 and IGFBP-3 can serve as early indicators of impending colorectal cancer. IGF-2/IGF-II appears to be involved in the progression of many tumours. It binds to at least two different types of receptor: IGF type 1 (IGF 1R) and mannose 6-phosphate/IGF type 2 (M6-P/IGF 2R). Ligand binding to IGF 1R provokes mitogenic and anti-apoptotic effects. M6-P/IGF 2R has a tumour suppressor function—it mediates IGF 2 degradation. Mutation of M6-P/IGF 2R causes both diminished growth suppression and augmented growth stimulation. The aim of this study was to investigate the role of IGF 2 and its receptors (IGF 1R and IGF 2R) in human gastric cancer.